SecBot SecBot
SECBOTREPLAY Home › Report › ORKA

ORKA · ORKA-001 PASI 100 61% at Wk16

Oruka Therapeutics, Inc. · PRESS-RELEASE filed Nov 9, 2026 at 16:04 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 9, 2026 at 16:04 ET

Oruka reported a Q3 2026 net loss of $50.0M ($0.63 per share) vs consensus of -$0.62, with no revenue. The key positive was strong Phase 2b data for ORKA-001 showing 61% PASI 100 at Week 16, consistent with prior results, and plans to start Phase 3 in 1H 2027. Cash position remains strong at $1.2B.

  • Q3 2026 net loss $50.0M ($0.63 per share) vs consensus -$0.62
  • Cash, cash equivalents and marketable securities of $1.2B as of Sep 30, 2026
  • ORKA-001 Phase 2b EVERLAST-B: 61% PASI 100, 86% PASI 90 at Week 16 (high-dose 600mg)
  • EVERLAST-A Week 28 data showed deepening responses: 71% PASI 100, 87% PASI 90

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access